tiprankstipranks
Aurinia Pharmaceuticals (AUPH)
NASDAQ:AUPH

Aurinia Pharmaceuticals Stock Price & Analysis

1,747 Followers

AUPH Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$6.28 - $33.97
Previous Close$7.55
Volume1.58M
Average Volume (3M)2.35M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$286.40M
Total Debt (Recent Filing)$8.22M
P/E Ratio-6.5
Beta0.77
Next EarningsNov 15, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-1.16
Shares Outstanding128,225,927
R-Squared0.03
Standard Deviation0.26
10 Day Avg. Volume1,862,079
30 Day Avg. Volume2,347,287
P/B Ratio2.56
P/S Ratio11.44
P/CF RatioN/A
P/FCF Ratio-10.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside140.13% Upside
Rating ConsensusStrong Buy
Alpha0.02
Number of Analyst Covering5


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

AUPH FAQ

What was Aurinia Pharmaceuticals’s price range in the past 12 months?
Aurinia Pharmaceuticals lowest stock price was $6.28 and its highest was $33.97 in the past 12 months.
    What is Aurinia Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Aurinia Pharmaceuticals’s upcoming earnings report date?
    Aurinia Pharmaceuticals’s upcoming earnings report date is Nov 15, 2022 which is in 39 days.
      How were Aurinia Pharmaceuticals’s earnings last quarter?
      Aurinia Pharmaceuticals released its earnings results on Aug 04, 2022. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.221 by -$0.029.
        Is Aurinia Pharmaceuticals overvalued?
        According to Wall Street analysts Aurinia Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Aurinia Pharmaceuticals pay dividends?
          Aurinia Pharmaceuticals does not currently pay dividends.
          What is Aurinia Pharmaceuticals’s EPS estimate?
          Aurinia Pharmaceuticals’s EPS estimate is -$0.23.
            How many shares outstanding does Aurinia Pharmaceuticals have?
            Aurinia Pharmaceuticals has 141,892,180 shares outstanding.
              What happened to Aurinia Pharmaceuticals’s price movement after its last earnings report?
              Aurinia Pharmaceuticals reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.221. Following the earnings report the stock price went up 0.235%.
                Which hedge fund is a major shareholder of Aurinia Pharmaceuticals?
                Among the largest hedge funds holding Aurinia Pharmaceuticals’s share is Diamond Hill Capital Management Inc. It holds Aurinia Pharmaceuticals’s shares valued at 287K.

                  ---

                  Aurinia Pharmaceuticals Stock Analysis

                  Smart ScoreNeutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  5
                  The Aurinia Pharmaceuticals stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Aurinia Pharmaceuticals

                  Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. The company was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Xenon
                  Repare Therapeutics
                  Zymeworks

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis